Search results for "VOLUME"

showing 10 items of 1932 documents

Airway Responsiveness to Histamine in Patients Refractory to Repeated Exercise

1988

To investigate the mechanisms contributing to refractoriness in exercise-induced asthma (EIA), airway responsiveness to histamine was studied in eight asthmatic patients. Patients were included in the study on the basis of their refractory response to multiple exercise challenges. Incremental challenges with inhaled histamine were performed at rest and 40 minutes after single and paired exercise tests. The geometric mean histamine concentration required to produce a 20 percent fall in FEV1 (PC20) for the challenge after paired exercise test (4.34 mg/ml) was significantly higher (p greater than 0.001) than those for the challenges after a single exercise (1.05 mg/ml) and for the challenge at…

AdultMalePulmonary and Respiratory MedicineTime FactorsRefractory periodPhysical ExertionCritical Care and Intensive Care MedicineBronchial Provocation Testschemistry.chemical_compoundRefractoryForced Expiratory VolumeHumansMedicineAsthmatic patientIn patientAsthmabusiness.industryRespiratory diseasemedicine.diseaseAsthmaAsthma Exercise-InducedchemistryAnesthesiaExercise TestFemaleCardiology and Cardiovascular MedicinebusinessAirway responsivenessHistamineHistamineChest
researchProduct

Characteristics and Prognostic Value of Morning Dipping of Peak Expiratory Flow Rate in Stable Asthmatic Subjects

1985

Characteristics and prognostic relevance of morning dip of peak expiratory flow rate (PEFR) were evaluated in stable asthmatic subjects. Among 246 outpatients monitored four times daily for two weeks, 38 (group A) showed a significant difference between morning reading of PEFR and each of the others; they were compared to 38 randomly selected patients (group B) not showing morning dip in PEFR. Less frequent seasonal course, extrinsic pathogenesis, and sensitization to mites characterized group A; starting airflow limitation was more severe in those with morning dip, but no significant difference between mean PEFR measured throughout two weeks was found. At 6 to 12 weeks, morning dip was not…

AdultMalePulmonary and Respiratory Medicinebusiness.industrySignificant differenceSeasonal coursePeak Expiratory Flow RateForced Expiratory Flow RatesMiddle AgedPrognosisCritical Care and Intensive Care Medicinemedicine.diseaseAsthmaCircadian RhythmPeak expiratory flow rate measurementForced Expiratory VolumeAnesthesiamedicineHumansFemaleRisk factorCardiology and Cardiovascular MedicinebusinessAsthmaMorningChest
researchProduct

Effect of QVA149 on lung volumes and exercise tolerance in COPD patients: The BRIGHT study

2014

Summary Introduction QVA149 is a novel, inhaled, once-daily dual bronchodilator containing a fixed-dose combination of the long-acting β 2 -agonist indacaterol and the long-acting muscarinic antagonist glycopyrronium (NVA237), for the treatment of chronic obstructive pulmonary disease (COPD). This study evaluated the effects of QVA149 on exercise tolerance, hyperinflation, lung function and lung volumes versus placebo and tiotropium. Methods Patients with moderate-to-severe COPD were randomized to QVA149 110/50 μg, placebo or tiotropium 18 μg once daily in a blinded, 3-period crossover study for 3 weeks. The primary endpoint was exercise endurance time at Day 21 for QVA149 versus placebo. R…

AdultMalePulmonary and Respiratory Medicinemedicine.drug_classVital CapacityScopolamine DerivativesHyperinflationQuinolonesPlaceboDrug Administration SchedulePulmonary Disease Chronic ObstructiveFunctional residual capacityDouble-Blind MethodForced Expiratory VolumeBronchodilatormedicineClinical endpointHumansLung volumesTiotropium BromideExerciseAgedCOPDCross-Over StudiesExercise Tolerancebusiness.industryChronic obstructive pulmonary diseaseTiotropiumQVA149Middle Agedmedicine.diseaseGlycopyrrolateCrossover studyBronchodilator Agentsrespiratory tract diseasesDrug CombinationsTreatment OutcomeSpirometryAnesthesiaIndansIndacaterolFemaleLung Volume Measurementsbusinessmedicine.drugRespiratory Medicine
researchProduct

Omalizumab in patients with severe persistent allergic asthma in a real-life setting in Germany

2009

Omalizumab is a humanized monoclonal anti-immunoglobulin E (IgE) antibody indicated in Europe for the treatment of uncontrolled severe persistent allergic (IgE-mediated) asthma despite optimal therapy with inhaled corticosteroids and long-acting beta(2) agonists. Between 2005 and 2007 280 patients (58% female, mean age 44+/-16 yrs., 46% on oral corticosteroids, median serum IgE level 235IU/ml) who met the EU criteria for add-on therapy with anti-IgE were treated prospectively with omalizumab by 134 physicians as part of a post-marketing surveillance trial and were followed-up for 6 months. The median follow-up time was 195 days, the patients were treated with a median dose of 450mg omalizum…

AdultMalePulmonary and Respiratory Medicinemedicine.medical_specialtyAllergyAdolescentAllergyOmalizumabOmalizumabAntibodies Monoclonal HumanizedImmunoglobulin ESeverity of Illness IndexYoung AdultQuality of lifeAdrenal Cortex HormonesForced Expiratory VolumeGermanyInternal medicineSeverity of illnessHypersensitivityHumansMedicineAnti-Asthmatic AgentsProspective StudiesChildProspective cohort studyAdverse effectAsthmaDose-Response Relationship Drugbiologybusiness.industryAntibodies MonoclonalMiddle Agedmedicine.diseaseAsthmaAntibodies Anti-IdiotypicSurgeryTreatment Outcomebiology.proteinFemaleIgETherapybusinessmedicine.drugRespiratory Medicine
researchProduct

Differences in sensitivity, maximal response and position of the concentration-response curve to methacholine between asthmatics, patients with aller…

1998

The aim of this study was to detect differences in maximal response and position of the concentration-response curves to methacholine between asthmatics and subjects with allergic rhinitis. A total of 228 adults (107 mild asthmatics, 96 allergic rhinitics and 25 healthy control subjects) were challenged with methacholine. The test was interrupted when FEV1 dropped by more than 40% or when the highest concentration of methacholine (200 mg ml-1) had been administered. Concentration-response curves were characterized by their PC20 (concentration of methacholine that produced 20% fall in FEV1 = airway sensitivity), and if possible, by their EC50 (concentration of methacholine that produced 50% …

AdultMalePulmonary and Respiratory Medicinemedicine.medical_specialtyAllergyGastroenterologySensitivity and SpecificityBronchoconstrictor AgentsInternal medicinemedicineHumansLung volumesMethacholine ChlorideAsthmaEC50RhinitisSkin TestsAnalysis of VarianceConcentration ResponseDose-Response Relationship Drugbusiness.industrymedicine.diseaseAsthmaRespiratory Function TestsDose–response relationshipAnesthesiaMethacholineFemaleAnalysis of varianceBronchial Hyperreactivitybusinessmedicine.drugRespiratory Medicine
researchProduct

Cigarette Smoking, But Not Sensitization toAlternaria, Is Associated with Severe Asthma in Urban Patients

2001

Hereditary susceptibility and allergen exposure have been identified as general risk factors for asthma. However, risk factors for severe asthma still remain to be identified. To further assess and quantify risk factors associated with severe asthma in adult patients apart from clinical exacerbations, 306 randomly selected subjects (mean age 40+/-17 years, 46% males) presenting to an inner city pulmonary practice between 1995 and 1996 were retrospectively investigated. Of these, 117 patients were atopic, 112 had current asthma, and 22 asthmatics had severe asthma. Risk factors associated with atopy were family history of atopy and any domestic pet ownership (OR: 3.1, 95% CI: 1.64-6.1). Asth…

AdultMalePulmonary and Respiratory Medicinemedicine.medical_specialtyAllergyUrban Populationmedicine.disease_causeSeverity of Illness IndexAtopyAllergenRisk FactorsForced Expiratory VolumeGermanyInternal medicineImmunopathologyHypersensitivitymedicineHumansImmunology and AllergyFamily historyRisk factorRetrospective StudiesAsthmabusiness.industrySmokingRespiratory diseaseUrban HealthAlternariamedicine.diseaseAsthmarespiratory tract diseasesMultivariate AnalysisPediatrics Perinatology and Child HealthImmunologyFemalebusinessJournal of Asthma
researchProduct

Rapid left ventricular filling in untreated hypertensive subjects with or without left ventricular hypertrophy

1992

In this study, independent contribution of age, HR, BMI, casual and ambulatory blood pressure, LVM and LVEF in evaluating diastolic filling have been investigated in 34 never-treated hypertensive patients and in 15 healthy normotensive subjects. All the subjects were free from coronary artery disease, valvular disease, heart failure, renal disease and psychiatric problems. All the hypertensive subjects (never treated) were subgrouped according to presence or absence of LVH. The PFR decreased significantly and tPFR increased significantly in hypertensive patients in comparison with normotensive subjects and they did not change in the presence vs absence of LVH. The PFR was inversely correlat…

AdultMalePulmonary and Respiratory Medicinemedicine.medical_specialtyAmbulatory blood pressureSettore MED/09 - Medicina InternaDiastoleBlood PressureCritical Care and Intensive Care MedicineLeft ventricular hypertrophyVentricular Function LeftBlood Pressure Echocardiography Female Humans Hypertension/complications Hypertension/physiopathology* Hypertension/radionuclide imaging Hypertension/ultrasonography Hypertrophy Left Ventricular/complications Hypertrophy Left Ventricular/physiopathology* Hypertrophy Left Ventricular/radionuclide imaging Hypertrophy Left Ventricular/ultrasonography Male Middle Aged Radionuclide Angiography Ventricular Function Left*Coronary artery diseaseInternal medicinemedicineHumanscardiovascular diseasesRadionuclide AngiographyEjection fractionbusiness.industryMiddle Agedmedicine.diseaseSettore MED/11 - Malattie Dell'Apparato CardiovascolareMean blood pressureEchocardiographyHeart failureHypertensionCardiologyEnd-diastolic volumeFemaleHypertrophy Left VentricularCardiology and Cardiovascular Medicinebusiness
researchProduct

Prospective evaluation of current asthma control using ACQ and ACT compared with GINA criteria

2011

Background The goal of asthma treatment is to achieve and maintain current best control and reduce future risk of exacerbations and long-term morbidity. Objective To prospectively compare current asthma control as defined by ACQ (asthma control questionnaire) and ACT (asthma control test) criteria with the GINA (Global Initiative for Asthma) classification in treated patients in a real-life setting. Methods In 150 adult patients (48% male, age 46.3 ± 14.4 years., forced expiratory volume in 1 second [FEV 1 ], 2.3 ± 0.9 L or 78.5 ± 21.8% pred.), asthma control was evaluated using the GINA classification as the "true" and ACQ-7, ACQ-5, and ACT as "predictor" criteria. The relationship between…

AdultMalePulmonary and Respiratory Medicinemedicine.medical_specialtySevere asthmaImmunologySensitivity and SpecificitySeverity of Illness IndexProspective evaluationPredictive Value of TestsForced Expiratory VolumeSurveys and QuestionnairesInternal medicineAsthma controlmedicineHumansImmunology and AllergyProspective StudiesAsthmaAdult patientsbusiness.industryMiddle Agedmedicine.diseasePredictive valueAsthmaBronchodilator Agentsrespiratory tract diseasesUncontrolled asthmaAsthma Control QuestionnairePhysical therapyFemalebusinessAnnals of Allergy, Asthma & Immunology
researchProduct

Measurement of Fractional Exhaled Nitric Oxide: Comparison of Three Different Analysers

2019

<b><i>Background:</i></b> Fractional exhaled nitric oxide (FeNO) is a surrogate marker for airway inflammation, supporting the diagnostic pathway and treatment decisions for asthma patients. <b><i>Objectives:</i></b> Aim of this study was to compare the new analyser Vivatmo pro (Bosch, BV) with NIOX VERO (Circassia, CN) and CLD (Ecomedics, EC). <b><i>Methods:</i></b> In 100 asthmatics (median 53 years [range 20–87], 62% female, 86% on inhaled corticosteroids [mean 1,300 μg beclomethasone dipropionate or equivalent], 35% treated with biologics) 2 FeNO measurements per device were performed. Additionally, the success rate…

AdultMalePulmonary and Respiratory Medicinemedicine.medical_specialtyVital CapacityAnalyserClinical InvestigationsUrologyInhaled corticosteroidsNitric OxideYoung Adult03 medical and health sciences0302 clinical medicineForced Expiratory VolumeHumansMedicineAnti-Asthmatic Agents030212 general & internal medicineAgedAsthmaAged 80 and overbusiness.industryAirway inflammationMiddle Agedrespiratory systemmedicine.diseaseAsthmarespiratory tract diseasesBreath Tests030228 respiratory systemExhaled nitric oxideFemaleTreatment decision makingbusinessRespiration
researchProduct

Serum low density lipoprotein subclasses in asthma

2013

Summary Background The levels of serum low-density lipoproteins (LDL) have been implicated in the inflammatory cascade in a murine model of asthma. Recent findings suggest that LDL may modulate the inflammatory state of the asthmatic airways in humans. Objective We explored whether LDL subclasses are associated with the occurrence and severity of asthma. Methods 24 asthmatics (M/F: 11/13) and 24 healthy individuals, with normal BMI and absence of metabolic syndrome, matched for age and gender. Serum concentrations of LDL subclasses were distributed as seven bands (LDL-1 and -2 defined as large, least pro-inflammatory LDL, and LDL-3 to −7 defined as small, most pro-inflammatory LDL), using t…

AdultMalePulmonary and Respiratory Medicinemedicine.medical_specialtyVital CapacityAsthma pathogenesiPilot ProjectsSettore MED/10 - Malattie Dell'Apparato RespiratorioFEV1Forced Expiratory VolumeInternal medicineStatistical significanceAsthma pathogenesisHumansMedicineAgedAsthmaLDL subclassesAged 80 and overDyslipidemia; Asthma pathogenesis; FEV1; LDL subclassesbusiness.industryMiddle AgedSerum concentrationHypolipoproteinemiasmedicine.diseaseAsthmaLipoproteins LDLEndocrinologyDyslipidemiaMurine modelInflammatory cascadeFemaleSerum low density lipoproteinlipids (amino acids peptides and proteins)Metabolic syndromebusinessDyslipidemiaRespiratory Medicine
researchProduct